{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T01:46:14Z","timestamp":1778982374493,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vph.2022.106974","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T04:49:47Z","timestamp":1646369387000},"page":"106974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Beta-blockers in pulmonary arterial hypertension: Time for a second thought?"],"prefix":"10.1016","volume":"144","author":[{"given":"R.","family":"Badagliacca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Correale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Masarone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.G.","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Agostoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2022.106974_bb0005","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.jacc.2018.12.076","article-title":"Anatomy, function, and dysfunction of the right ventricle: JACC state-of-the-art review","volume":"73","author":"Sanz","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2022.106974_bb0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1183\/09059180.00007109","article-title":"Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart","volume":"19","author":"Handoko","year":"2010","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.vph.2022.106974_bb0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0014-2999(87)90798-9","article-title":"Alterations in cardiac beta-adrenoceptor responsiveness and adenylate cyclase system by congestive heart failure in dogs","volume":"140","author":"Fan","year":"1987","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.vph.2022.106974_bb0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/682223","article-title":"The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series)","author":"Bristow","year":"2015","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.vph.2022.106974_bb0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ejhf.253","article-title":"Sympathetic nervous system activation and \u03b2-adrenoceptor blockade in right heart failure","volume":"17","author":"Andersen","year":"2015","journal-title":"Eur. J. Heart Failure."},{"key":"10.1016\/j.vph.2022.106974_bb0030","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1172\/JCI115659","article-title":"Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms","volume":"89","author":"Bristow","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2022.106974_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894019868620","article-title":"Cardiac sympathetic dysfunction in pulmonary arterial hypertension: lesson from left-sided heart failure","volume":"9","author":"Mercurio","year":"2019","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.vph.2022.106974_bb0040","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jacbts.2019.05.011","article-title":"Epigenetics in cardiac hypertrophy and heart failure","volume":"4","author":"Chia-Feng","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.vph.2022.106974_bb0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2015.03.422","article-title":"Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure","volume":"189","author":"Apostolo","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2022.106974_bb0050","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/2047487313497866","article-title":"Inside ventilatory regulation in pulmonary hypertension: several hidden data are still undiscovered","volume":"21","author":"Agostoni","year":"2014","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.vph.2022.106974_bb0055","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0735-1097(02)02964-9","article-title":"Pulmonary function in primary pulmonary hypertension","volume":"41","author":"Sun","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2022.106974_bb0060","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijcard.2017.11.023","article-title":"Physiological insights of exercise hyperventilation in arterial and chronic thromboembolic pulmonary hypertension","volume":"259","author":"Farina","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2022.106974_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061877","article-title":"Role of alveolar beta2-adrenergic receptors on lung fluid clearance and exercise ventilation in healthy humans","volume":"8","author":"Paolillo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2022.106974_bb0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1465-9921-14-6","article-title":"Loss of alveolar membrane diffusing capacity and pulmonary capillary blood volume in pulmonary arterial hypertension","volume":"14","author":"Farha","year":"2013","journal-title":"Respir. Res."},{"key":"10.1016\/j.vph.2022.106974_bb0075","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1164\/rccm.200404-470CP","article-title":"Alveolar epithelial beta 2-adrenergic receptors: their role in regulation of alveolar active sodium transport","volume":"170","author":"Mutlu","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.vph.2022.106974_bb0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.resp.2013.04.005","article-title":"Acute high-altitude exposure reduces lung diffusion: data from the HIGHCARE Alps project","volume":"188","author":"Agostoni","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.vph.2022.106974_bb0085","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ijcard.2013.01.277","article-title":"Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial","volume":"168","author":"Contini","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.vph.2022.106974_bb0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1755-5922.2011.00306.x","article-title":"Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity","volume":"31","author":"Ladage","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.vph.2022.106974_bb0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1007784109255","article-title":"Beta-blocker selectivity at cloned human beta1- and beta2-adrenergic receptors","volume":"13","author":"Smith","year":"1999","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.vph.2022.106974_bb0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/CIRCHEARTFAILURE.111.964494","article-title":"Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension","volume":"5","author":"De Man","year":"2012","journal-title":"Circ. Heart Fail."},{"issue":"5","key":"10.1016\/j.vph.2022.106974_bb0105","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1164\/rccm.201003-0335OC","article-title":"Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats","volume":"182","author":"Bogaard","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.vph.2022.106974_bb0110","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physiolgenomics.00166.2012","article-title":"Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension","volume":"45","author":"Drake","year":"2013","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.vph.2022.106974_bb0115","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00109-015-1251-9","article-title":"Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension","volume":"93","author":"Okumura","year":"2015","journal-title":"J. Mol. Med. (Berl)."},{"key":"10.1016\/j.vph.2022.106974_bb0120","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.fjc.0000201359.58174.c8","article-title":"Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension","volume":"47","author":"Fujio","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.vph.2022.106974_bb0125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yjmcc.2018.05.015","article-title":"Beta1-adrenoceptor antagonist, metoprolol attenuates cardiac myocyte Ca2+ handling dysfunction in rats with pulmonary artery hypertension","volume":"120","author":"Fowler","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.vph.2022.106974_bb0130","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jacc.2014.11.050","article-title":"Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension","volume":"65","author":"Perros","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2022.106974_bb0135","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2011.02.020","article-title":"Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists","volume":"57","author":"Hawkins","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2022.106974_bb0140","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1139\/cjpp-2015-0431","article-title":"Nebivolol has a beneficial effect in monocrotaline-induced pulmonary hypertension","volume":"94","author":"Pankey","year":"2016","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.vph.2022.106974_bb0145","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/1440-1681.12898","article-title":"Diastolic dysfunction in pulmonary artery hypertension: creatine kinase and the potential therapeutic benefit of beta-blockers","volume":"45","author":"Fowler","year":"2018","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.vph.2022.106974_bb0150","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2005.10.013","article-title":"Deleterious effects of B-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension","volume":"130","author":"Provencher","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vph.2022.106974_bb0155","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1183\/09031936.00215514","article-title":"Outcomes of \u03b2-blocker use in pulmonary arterial hypertension: a propensity-matched analysis","volume":"46","author":"Bandyopadhyay","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.vph.2022.106974_bb0160","first-page":"617","article-title":"Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study","volume":"48","author":"Jasmijn","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"16","key":"10.1016\/j.vph.2022.106974_bb0165","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95240","article-title":"Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial","volume":"2","author":"Farha","year":"2017","journal-title":"JCI Insight"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189122000234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189122000234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:21:06Z","timestamp":1761528066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189122000234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":33,"alternative-id":["S1537189122000234"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2022.106974","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-blockers in pulmonary arterial hypertension: Time for a second thought?","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2022.106974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106974"}}